Passage Bio, Inc. (PASG) has a negative trailing P/E of -0.8, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -131.63%.
Criteria proven by this page:
Overall SharesGrow Score: 51/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2018 | -41.7 | 0.00 | -43.70 | 0.00 | - |
| 2019 | -11.7 | -0.04 | 3.05 | 0.00 | - |
| 2020 | -10.4 | -0.39 | 3.83 | 0.00 | - |
| 2021 | -1.8 | -0.09 | 1.06 | 0.00 | - |
| 2022 | -0.6 | 0.02 | 0.37 | 0.00 | - |
| 2023 | -0.5 | 0.02 | 0.50 | 0.00 | - |
| 2024 | -0.5 | 0.01 | 0.56 | 0.00 | - |
| 2025 | -0.8 | 0.02 | 2.00 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2018 | $-0.53 | $0.00 | $-12.77M | - |
| 2019 | $-1.19 | $0.00 | $-54.58M | - |
| 2020 | $-2.89 | $0.00 | $-112.23M | - |
| 2021 | $-3.48 | $0.00 | $-185.39M | - |
| 2022 | $-2.50 | $0.00 | $-136.13M | - |
| 2023 | $-1.86 | $0.00 | $-102.06M | - |
| 2024 | $-1.07 | $0.00 | $-64.77M | - |
| 2025 | $-14.35 | $0.00 | $-45.52M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-8.56 | $-14.43 – $-3.07 | $2M | $2M – $2M | 5 |
| 2027 | $-5.58 | $-11.58 – $-1.37 | $45.01M | $45.01M – $45.01M | 4 |
| 2028 | $-4.31 | $-11.40 – $-0.75 | $31.53M | $31.53M – $31.53M | 4 |
| 2029 | $-4.32 | $-4.32 – $-4.32 | $15.03M | $15.03M – $15.03M | 2 |
| 2030 | $-1.13 | $-1.13 – $-1.13 | $43.56M | $43.56M – $43.56M | 2 |
